Cigna earnings beat by $0.04, revenue topped estimates
WALTHAM, MA – NeuroMetrix , Inc. (NASDAQ:NURO), a medical device company with a market capitalization of $9.43 million, has been acquired by electroCore, Inc., a move that was finalized on May 1, 2025. The completion of the merger, initially announced on December 17, 2024, results in NeuroMetrix becoming a wholly-owned subsidiary of electroCore.
Under the terms of the agreement, each share of NeuroMetrix common stock was converted into the right to receive a pro rata share of the company’s net cash balance, which amounted to $4.49 per share, along with one contingent value right (CVR). The CVR entitles the holder to potential future payments based on the sale of products under NeuroMetrix’s Quell product line and other criteria specified in the agreement.
Following the merger, NeuroMetrix requested the suspension of trading of its common stock on The Nasdaq Capital Market before the market opened today, May 2, 2025, and will file a Form 25 with the SEC to delist and deregister its common stock under Section 12(b) of the Securities Exchange Act of 1934. The stock’s final trading price of $4.58 was near its 52-week high of $4.73, as reported by InvestingPro. Additionally, NeuroMetrix plans to file a Form 15 with the SEC to terminate the registration of its securities and suspend its reporting obligations.
The merger also led to changes in the company’s leadership and board of directors. As of the effective time of the merger, the existing directors of NeuroMetrix ceased to serve, and Dan Goldberger and Joshua Lev, the directors of the merger subsidiary prior to the effective time, assumed their positions on the board of the surviving corporation. Goldberger has become the Chief Executive Officer and Lev the Chief Financial Officer of the surviving corporation.
The merger represents a significant change in control for NeuroMetrix, with electroCore funding the transaction through its cash on hand. This news is based on a press release statement.
In other recent news, NeuroMetrix shareholders have approved a merger with electroCore, a significant development for both companies. The merger agreement received substantial support, with 1,110,697 votes in favor and only 16,676 against, during a virtual special meeting. This merger aims to enhance the combined company’s capabilities and market reach, although it is still subject to certain closing conditions. These include the finalization of net cash determinations and the filing of NeuroMetrix’s annual report for the fiscal year ending December 31, 2024. Additionally, stockholders approved a non-binding advisory proposal regarding executive compensation related to the merger, with 1,032,991 votes in favor. The merger is expected to be finalized in the last week of April 2025, marking a strategic move for NeuroMetrix to strengthen its portfolio and market position. These developments highlight the company’s efforts to expand its presence in the medical device industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.